Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 18 October 2025 - 21 October 2025

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) Globenewswire. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) Globenewswire. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) Globenewswire Stocktitan. Early trial data for…
21 October 2025
····
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance Stockanalysis Stockanalysis Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) Stockanalysis. Trading volume is light (hundreds of thousands of shares), and the stock’s beta (~1.46) indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3…
21 October 2025
···
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the day Finviz. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart –…
20 October 2025
···
Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intraday Marketbeat, an approximately 40–50% single-day leap, before settling near a record high close. This surge marked a new 52-week high of $81.56 Marketbeat and lifted Celcuity’s…
20 October 2025
····
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Alliance Triggers Record Rally GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and become the exclusive distributor of the Galleri multi-cancer blood test in South Korea, with rights to expand into Japan and Singapore ts2.tech. Samsung Electronics is also participating and…
20 October 2025
···
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake (~5.7M shares) in SLS on Oct. 18…
20 October 2025
····
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 Marketbeat, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursday Vikingtherapeutics. This marks a dramatic recovery…
19 October 2025
···
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in…
19 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test Samsung Tradingview. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can be cured” Samsung. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic…
18 October 2025
····
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 Stockanalysis Marketbeat. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average)…
18 October 2025
···
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 on unusually heavy volume ts2.tech. After a brief mid-week pullback on profit-taking (shares dipped ~4%…
18 October 2025
···
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 Stockanalysis Stockanalysis. That rally marked a new 2025 high for the biotech…
18 October 2025
····
1 … 18 19 20 21 22 … 24

Stock Market Today

  • Hedge Funds Increase Southern Company (SO) Holdings by 3.83% in Latest 13F Filings
    February 2, 2026, 10:27 AM EST. Recent 13F filings for the 03/31/2025 period reveal that 14 hedge funds hold Southern Company (SO). Among these, five increased and five decreased their positions since 12/31/2024. Aggregate shares held by hedge funds rose by approximately 3.83%, with a net addition of 1.13 million shares, climbing from 29.39 million to 30.52 million shares. While 13F reports disclose only long positions, making it hard to see full market sentiment, collective trends offer insights. This rise in holdings highlights interest in SO among institutional investors, warranting further research. Observers will watch future 13F filings to track shifts in hedge fund strategies regarding Southern Company and potential stock opportunities.
Go toTop